SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rashid MH,Chaudhary UB. Intermittent androgen deprivation therapy for prostate cancer. Oncologist. 2004; 9: 295301.
  • 2
    Bhandari MS,Crook J,Hussain M. Should intermittent androgen suppression be used in routine clinical practice? J Clin Oncol. 2005; 23: 82128218.
  • 3
    Pether M,Goldenberg SL,Bhagirath K,Gleave M. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience. Can J Urol. 2003; 10: 17371742.
  • 4
    Akakura K,Bruchovsky N,Goldenberg SL,Rennie PS,Buckley AR,Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer. 1993; 71: 27822790.
  • 5
    Sadar MD,Hussain M,Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. Endocrine Relat Cancer. 1999; 6: 487502.
  • 6
    Bruchovsky N,Klotz L,Crook J, et al. Final results of the Canadian prospective Phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. Cancer. 2006; 107: 389395.
  • 7
    Plymate SR,Tenover JS,Bremner WJ. Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J Androl. 1989; 10: 366371.
  • 8
    Nejat RJ,Rashid HH,Bagiella E, et al. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol. 2000; 164: 18911894.
  • 9
    Gulley JL,Figg WD,Steinberg SM, et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized Phase III clinical trial using limited hormonal therapy. J Urol. 2005; 173: 15671571.
  • 10
    Albrecht W,Collette L,Fava C, et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol. 2003; 44: 505511.
  • 11
    Prapotnich D,Fizazi K,Escudier B,Mombet A,Cathala N,Vallancien G. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol. 2003; 43: 233239.
  • 12
    Scholz MC,Trilling T,Brosman SA, et al. PSA nadir greater than 0.6 on combined hormonal blockade (CHB) predicts the early development of androgen independent prostate cancer (AIPC) in men with PSA relapse after local therapy [abstract]. Proc Western Amer Urol Assoc. 2003. Abstract 09-43.
  • 13
    Malone S,Perry G,Segal R,Dahrouge S,Crook J. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a Phase II study. BJU Int. 2005; 96: 514520.